After elucidating the role of UDP-GlcA in suppressing TNFα-induced RIPK1 activation and apoptosis, we next evaluated the potential therapeutic effect of UDP-GlcA against NASH-associated liver damage in mice. This evidence concerns the gene RIPK1 and metabolic dysfunction-associated steatohepatitis.